Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026
19 Aug, 2016, 14:00 BST
LONDON, August 19, 2016 /PRNewswire/ --
Mammalian Cell Culture, Microbial Fermentation, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccine
Biological Drug API Manufacturing Services World Industry and Market Predictions 2016-2026: Mammalian Cell Culture, Microbial Fermentation, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccine reviews the contract active pharmaceutical ingredient (API) manufacturing market for biologics. This study gives quantitative and qualitative analysis for that overall world market, as well as for countries and other submarkets, including the mammalian cell culture and microbial fermentation segments. This report assesses leading applications and significant developments within each, as well as drivers and restraints for them. Future trends that will affect the biotech API manufacturing services market are also examined. In addition, this study profiles leading contract manufacturing organisations (CMOs) in the outsourcing market and assesses their outlooks. Visiongain provides forecasts revenues for the period 2015 to 2026 for the biotech API manufacturing services market, as well as for therapeutic applications.
How this 238 page report delivers:
• Provides qualitative and quantitative analysis of the leading submarkets the period 2015-2026. Visiongain forecasts revenues and their growth for these submarkets:
- Mammalian cell culture
- Microbial fermentation
- Other expression platforms
• Provides qualitative and quantitative analysis of the leading contract API biological drug applications for the period 2015-2026. Visiongain forecasts contract API drug revenues to 2026 for these individual segments:
- Monoclonal antibody (mAb) therapies
- Vaccines
- Insulin therapies
- Interferon therapies
- Growth hormones
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
• Find forecasts of the leading therapeutic and national markets from 2015 to 2026:
- The EU, including the five leading markets (UK, Germany, France, Italy and Spain).
- The US
- Japan
- Switzerland
- Emerging markets such as the BRIC (Brazil, Russia, India, and China) countries, South Korea and Singapore.
• Profiles leading global and national companies that offer biotech API manufacturing services to the pharmaceutical industry. For each company, current services offered, recent developments and outlooks are discussed. Leading CMOs profiled in this chapter are:
- Boehringer Ingelheim BioXcellence
- Celltrion
- DSM Biologics
- Lonza
- Samsung BioLogics
- Cytovance Biologics
- Fujifilm Diosynth Biotechnologies
- Operations of leading biopharma companies, such as AbbVie, GSK and Novartis.
• Discover the regulatory outlook for biotech API manufacturing in leading regional and national markets in 2016, as well as predicted developments for the period to 2026.
• Read expert opinions from other authorities on the biotech API manufacturing industry.
• Identify important drug development and technology trends that will affect CMOs, their clients and other market participants from 2016. The report also contains SWOT and STEP analysis of the industry and market.
• Find profiles for leading CMOs offering biological drug API manufacturing services to pharmaceutical companies.
How This Report Delivers: Chapter Summary
This updated study provides an overview of the subject along with qualitative and quantitative analyses of the biotech API manufacturing services market. This report contains expert opinions from industry participants. In more detail, the chapters of this report contain the following information:
Chapter 1 forms a report overview.
Chapter 2 defines the biotech API manufacturing services market and provides an introduction to that industry.
Chapter 3 quantitatively assesses the world market for biotech API manufacturing services revenues. The chapter provides an estimate for the size of the market in 2015 and forecasts revenues for the period 2015-2026. Visiongain discusses the main drivers and restraints on the market for a 10-year forecast period.
Chapter 4 provides qualitative and quantitative analysis of the leading submarkets the period 2015-2026. Visiongain forecasts revenues and their growth for these submarkets:
• Mammalian cell culture
• Microbial fermentation
• Other expression platforms.
For the leading submarkets, we analyse commercial drivers and restraints, as well as forecasting revenues to 2026.
Chapter 5 provides qualitative and quantitative analysis of the leading contract API biological drug applications for the period 2015-2026. Visiongain forecasts contract API drug revenues to 2026 for these individual segments:
• Monoclonal antibody (mAb) therapies
• Vaccines
• Insulin therapies
• Interferon therapies
• Growth hormones.
Chapter 6 forecasts the leading national submarkets for biotech API manufacturing services, for the period 2015-2026. That section also provides quantitative analysis. The chapter offers a regional breakdown of the market by market share, and also discusses developments and future expectations for each main national submarket. National submarkets forecasted in this chapter are these:
• The EU, including the five leading markets (UK, Germany, France, Italy and Spain).
• The US
• Japan
• Switzerland
• Emerging markets such as the BRIC (Brazil, Russia, India, and China) countries, South Korea and Singapore.
Chapter 7 profiles leading global and national companies that offer biotech API manufacturing services to the pharmaceutical industry. For each company, current services offered, recent developments and outlooks are discussed. Leading CMOs profiled in this chapter are:
• Boehringer Ingelheim BioXcellence
• Celltrion
• DSM Biologics
• Lonza
• Samsung BioLogics
• Cytovance Biologics
• Fujifilm Diosynth Biotechnologies
• Operations of leading biopharma companies, such as AbbVie, GSK and Novartis.
Chapter 8 provides qualitative analysis of the biotech API manufacturing services market from 2015. That chapter identifies main strengths and weaknesses of the market, as well as opportunities and threats facing CMOs to 2026. Social, technological, economic and political (STEP) factors affecting market growth are also discussed. Industry trends and regulatory developments affecting the market are discussed.
Chapter 9 provides transcripts of interviews conducted by visiongain with other authorities. For this report, visiongain interviewed the following authorities on the CMO industry:
• Steve Bagshaw, CEO, Fujifilm Diosynth Biotechnologies, UK.
• Jon S. Gingrich, Manager of Business Development, Avid Bioservices Inc., US.
Chapter 10 summarises the report, highlighting conclusions from visiongain's research and analysis.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
To request a report overview of this report please emails Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100
Companies and Other Organisations Mentioned
3P Biopharmaceuticals
AbbVie
AbbVie Contract Manufacturing (part of AbbVie)
Adocia
Ajinomoto Omnichem
Ambrx
Amgen
Aptuit
arGEN-X N.V.
AstraZeneca
Avid Bioservices (part of Peregrine Pharmaceuticals)
Bachem
Banner Life Sciences (part of DPx Holdings)
BaroFold
Baxter International
Bayer
Biocad
Bioceuticals Arzneimittel (part of Stada)
Biocon
Biogen Idec
Bioplanta
Boehringer Ingelheim
Boehringer Ingelheim BioXcellence (part of Boehringer Ingelheim)
Bristol-Myers Squibb
Calico Life Sciences
Carbogen Amcis
Catalent
Celltrion
Cinfa
CMC Biologics
Cytovance Biologics
DPx Fine Chemicals (part of DPx Holdings)
DPx Holdings
DSM Biologics (was part of Royal DSM, now part of DPx Holdings)
DSM Sinochem Pharmaceuticals (part of DPx Holdings)
Eisai
Eli Lilly
EMD Millipore (part of Merck)
European Medicines Agency (EMA)
Ferring Pharmaceuticals
Food and Drug Administration (US FDA)
Fujifilm
Fujifilm Diosynth Biotechnologies (part of Fujifilm)
Gallus Biopharmaceuticals (part of DPx Holdings)
GE Healthcare
Genentech (part of Roche)
Genmab
Genzyme (part of Sanofi)
Gilead Sciences
GlyTech
Granules
GSK
GSK Biopharmaceuticals (part of GSK)
Hexal (part of Novartis)
Hospira
Hospira One2One (part of Hospira)
Infinity Pharmaceuticals
International Diabetes Federation
Ipsen
Kalon Biotherapeutics (part of Fujifilm)
Korea Food and Drug Administration (KFDA)
Kyowa Hakko Kirin
Laureate Biopharma (part of DPx Holdings)
Lek Pharmaceuticals (Sandoz)
Lonza
Medice
Merck & Co.
Merck Biomanufacturing Network
Merck KGaA
Merck Millipore
Merck Serono
Millennium Pharmaceuticals
Millhouse LLC
Ministry for Food and Drug Safety [Korea]
Ministry of Health [Brazil]
Mitsubishi Gas Chemical Company
Mylan
Neopharm
Nikon
Norbitec
Nordmark Arzneimittel
Novartis
Novasep
Novo Nordisk
Nuron Biotech
Nycomed
Open Monoclonal Technology (OMT)
Opko Health
Patheon (part of DPx Holdings)
Patheon Biologics(part of DPx Holdings)
Peregrine Pharmaceuticals
Perrigo
Pfizer
Pharmacyclics
Pharmstandard
Phyton Biotech
Piramal Healthcare
Precision Biologics
Prolor Biotech
Quintiles
Recepta Biopharma
Redwood Bioscience (part of Catalent)
Relthy Laboratórios (part of Catalent)
Rentschler Biotechnologie
Roche
Royal DSM (part of DPx Holdings)
SAFC (part of Sigma-Aldrich)
Samsung
Samsung Bioepis (part of Samsung)
Samsung BioLogics (part of Samsung)
Sandoz (part of Novartis)
Sanofi
Schering-Plough (part of Merck & Co.)
SCM Pharma
Seattle Genetics
ShangPharma
SICOR Biotech (part of Teva)
Stada Arzneimittel
Sunshine Biopharma
Takeda
TAPI (part of Teva)
Teva Pharmaceutical Industries
Tonghua Dongbao Pharmaceutical
Toyobo Biologics
Tufts Center for the Study of Drug Development (CSDD)
Vertex
Vida Pharma
World Health Organization (WHO)
WuXi PharmaTech
Xcellerex
Zhangjiang Biotech and Pharmaceutical Base Development (ZJ Base)
Zhejiang Jiang Yuan Tang Biotechnology
Zhuhai United Laboratories
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
SOURCE Visiongain Ltd
Share this article